JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5076
CALL
General Mills
GIS
$17.1B
| $312K | ﹤0.01% |
+4,900
| New | +$329K |
2024 Q4
0 quarters
|
|
5077
Schwab 1-5 Year Corporate Bond ETF
SCHJ
$865M
| $311K | ﹤0.01% |
12,756
-230
| -2% | -$5.64K |
2023 Q3
5 quarters
|
|
|
GRAL
5078
GRAIL Inc
GRAL
$6.4B
| $311K | ﹤0.01% |
17,404
-48,591
| -74% | -$790K |
2024 Q2
2 quarters
|
|
5079
PUT
Nasdaq
NDAQ
$50.5B
| $309K | ﹤0.01% |
+4,000
| New | +$309K |
2024 Q4
0 quarters
|
|
5080
Stereotaxis
STXS
$118M
| $307K | ﹤0.01% |
134,822
+110,909
| +464% | +$232K |
2020 Q2
18 quarters
|
|
5081
Northern Trust International Quality Dividend ETF
IQDF
$1.15B
| $302K | ﹤0.01% |
12,978
+2,752
| +27% | +$68.7K |
2022 Q3
9 quarters
|
|
5082
Distribution Solutions Group
DSGR
$1.62B
| $302K | ﹤0.01% |
8,771
+38
| +0.4% | +$1.46K |
2016 Q4
32 quarters
|
|
5083
Roadzen
RDZN
$104M
| $302K | ﹤0.01% |
138,352
+110,244
| +392% | +$136K |
2023 Q4
4 quarters
|
|
|
SBT
5084
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $302K | ﹤0.01% |
63,349
+40,318
| +175% | +$191K |
2018 Q1
27 quarters
|
|
5085
NLI Holdings
NL
$341M
| $301K | ﹤0.01% |
38,750
+16,393
| +73% | +$130K |
2016 Q4
32 quarters
|
|
|
RGLS
5086
DELISTED
Regulus Therapeutics
RGLS
| $301K | ﹤0.01% |
190,457
+111,485
| +141% | +$171K |
2023 Q3
5 quarters
|
|
|
SCPH
5087
DELISTED
scPharmaceuticals
SCPH
| $300K | ﹤0.01% |
84,827
+72,485
| +587% | +$278K |
2022 Q4
8 quarters
|
|
5088
Flotek Industries
FTK
$1.12B
| $300K | ﹤0.01% |
31,497
+30,732
| +4,017% | +$209K |
2015 Q4
36 quarters
|
|
|
SUNS
5089
Sunrise Realty Trust
SUNS
$83.8M
| $300K | ﹤0.01% |
21,280
+10,511
| +98% | +$152K |
2024 Q3
1 quarter
|
|
5090
Invesco S&P MidCap Low Volatility ETF
XMLV
$694M
| $299K | ﹤0.01% |
4,919
| – | – |
2018 Q1
27 quarters
|
|
|
TRML
5091
DELISTED
Tourmaline Bio
TRML
| $298K | ﹤0.01% |
14,705
-99
| -0.7% | -$2.49K |
2021 Q2
14 quarters
|
|
|
ORC
5092
Orchid Island Capital
ORC
$1.01B
| $297K | ﹤0.01% |
38,139
-23,386
| -38% | -$184K |
2017 Q4
28 quarters
|
|
5093
HireQuest
HQI
$261M
| $296K | ﹤0.01% |
20,939
+11,007
| +111% | +$156K |
2021 Q2
14 quarters
|
|
5094
CALL
Futu Holdings
FUTU
$14.3B
| $296K | ﹤0.01% |
3,700
-17,200
| -82% | -$1.61M |
2023 Q2
6 quarters
|
|
|
LNAI
5095
Lunai Bioworks
LNAI
$5.89M
| $296K | ﹤0.01% |
4,423
+3,260
| +280% | +$216K |
2023 Q4
4 quarters
|
|
5096
Peoples Bancorp of North Carolina
PEBK
$236M
| $295K | ﹤0.01% |
9,429
+5,063
| +116% | +$145K |
2023 Q4
4 quarters
|
|
5097
CALL
Vir Biotechnology
VIR
$1.89B
| $294K | ﹤0.01% |
+40,000
| New | +$316K |
2024 Q4
0 quarters
|
|
|
5098
PUT
Vir Biotechnology
VIR
$1.89B
| $294K | ﹤0.01% |
+40,000
| New | +$316K |
2024 Q4
0 quarters
|
|
|
JNPR
5099
CALL
DELISTED
Juniper Networks
JNPR
| $292K | ﹤0.01% |
7,800
| – | – |
2023 Q2
6 quarters
|
|
5100
NN Inc
NNBR
$372M
| $292K | ﹤0.01% |
89,265
+69,149
| +344% | +$264K |
2013 Q2
46 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.